Skip to content

Join Newsletter

Learn more about our upcoming Galas and Signature Events Learn More

Shop

Search For:

What’s Melanoma?
- Understanding Melanoma
Patient Care
Education
Research & Science
Our Work
How to Help
Events
About Us

Donate

More

Shop Donate

What’s Melanoma?
- Understanding Melanoma
Patient Care
Education
Research & Science
Our Work
How to Help
Events
About Us

January 27, 2025

Learn More About the MRF's Rebrand

View Press Release

Popular Resources

Cutaneous Melanoma Patient Guide Stages 0-1 Melanoma Research Foundation – Melanoma Patient Forum Melanoma Research Foundation Clinical Trial Finder Treatment Center Finder - Melanoma Research Foundation

Legacy of Progress Endowment Fund

MRF Merch – Shop for a Cause

BAP1 Dependent Kinome in Uveal Melanoma

Usman Baqai

Andrew Aplin, PhD

Medical Student Award

Sidney Kimmel Medical College at Thomas Jefferson University

Medical Student Award – Usman Baqai

Stay Updated With the MRF.

Join Our Newsletter

Join Newsletter

I AM...

New to Melanoma
Patient & Survivor
Caregiver
Research & Science
Advocate
Donor
Corporate Partner

Get Engaged

Donate Now
Shop the MRF
Ways to Give
Our Newsletter
Attend an Event
Join Patient Forum
View the Newsroom
Grants & RFPs

Explore

What’s Melanoma?
Patient Care
Education
Research & Science
Our Work
How to Help
Events
About Us

A 501(c)(3) Non-Profit Organization.

The Melanoma Research Foundation (MRF), a 501(c)(3) non-profit organization, is leading the melanoma community to transform melanoma from one of the deadliest cancers to one of the most treatable through research, education and advocacy.

© Copyright 2025 Melanoma Research Foundation (MRF)

Privacy Policy
Terms of Use

THE INFORMATION ON THIS WEBSITE IS FOR INFORMATION PURPOSES ONLY AND IS NOT A RECOMMENDATION OR ENDORSEMENT OF ANY DRUG, DEVICE OR TREATMENT OR THAT ANY PARTICULAR DRUG, DEVICE OR TREATMENT IS SAFE, APPROPRIATE OR EFFECTIVE FOR YOU. QUESTIONS REGARDING ANY DRUG, DEVICE OR TREATMENT SHOULD BE DIRECTED TO YOUR HEALTHCARE PROVIDER.